Vasoactive intestinal peptide as a bronchodilator in severe asthma.

Abstract

In two studies vasoactive intestinal peptide (VIP) was administered intravenously to two groups of eight in-patient volunteers recovering from severe acute asthma. VIP (6 pmol/kg/min) infusion caused significant (p less than 0.01) increase in peak expiratory flow rate (PEFR) of 26 +/- 9 (SEM) l/min after 30 minutes infusion compared with a bronchodilation of 39 +/- 19 l/min seen with salbutamol (5 mcg/min). Following pretreatment with nebulized ipratropium bromide, VIP infusion caused a significant (p less than 0.02) bronchodilation of 25 l/min. VIP is a bronchodilator in severe asthma, although its effects are less than conventional medication. Reflex mechanisms are unlikely to explain the bronchodilatory effect of intravenous VIP.

• Authors: A H Morice, P S Sever
• Journal: Peptides (Peptides) Vol. 7 Suppl 1 Pg. 279-80 ( 1986) ISSN: 0196-9781 [Print] United States
• PMID: 3529052 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Bronchodilator Agents
• Vasoactive Intestinal Peptide

Topics

• Adult
• Aged
• Asthma (drug therapy, physiopathology)
• Bronchodilator Agents
• Clinical Trials as Topic
• Humans
• Infusions, Parenteral
• Middle Aged
• Peak Expiratory Flow Rate
• Vasoactive Intestinal Peptide (administration & dosage, therapeutic use)